Eli Lilly and Co (LLY) News & EventsLLYNews & EventsEli Lilly and Co

Eli Lilly's Mounjaro Approved by FDA to Lower Cardiovascular Event Risk

Eli Lilly and Company announced that the U.S. FDA approved Mounjaro, a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular events, including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. Mounjaro is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes.

Canada Raises Tariffs on U.S. Steel and Aluminum to 50%

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.RETALIATORY TARIFFS:Canada is matching Trump's weekend tariff escalation with a sweeping package of counter tariffs that directly targets U.S. steel, aluminum and downstream manufacturing. Prime Minister Mark Carney will double Canada's existing counter-tariffs on U.S. steel and aluminum to 50%, while adding new 50% duties on U.S. furniture, clothing, electronics, smartphones, and gaming consoles. Overall, the retaliatory levies cover roughly $20B in annual imports. The measures take effect on September 8 and represent a sharp reversal in Carney's earlier conciliatory stance after trade talks between Canada and U.S. collapsed on Friday. Publicly traded companies in the space include ArcelorMittal, Cleveland-Cliffs, Nucor, Steel Dynamicsand U.S. Steel. Publicly traded companies in the aluminum space include Alcoa, Kaiser Aluminum, Rio Tinto, Century Aluminum, and Constellium.DEPUTY ROLES:The Department of Health and Human Services is planning to create two new deputy commissioner roles at the Food and Drug Administration, one of which would focus on technology and the intersection of health and artificial intelligence, CNBC's Annika Kim Constantino. The other new position is for a deputy commissioner for drugs, according to two sources familiar with the plan. Publicly-traded companies operating in the space include Pfizer, Merck, Bristol Myers, Eli Lilly, AbbVie, Amgen, Medtronic, Abbott, Boston Scientific, Stryker, Intuitive Surgical, GE HealthCare, Teladoc, and Oracle.U.S.-IRAN:In a post on Truth Social, President Trump stated, "The failing Islamic Republic of Iran is not paying large segments of their military, while at the same time killing protesters, even when they are not protesting, at levels not seen before. It is a humanitarian crisis of epic proportions, and must be stopped, NOW."

Eli Lilly Announces Zepbound Study Results Showing Reduced Healthcare Costs

Eli Lilly announced results from a real-world study of adults over 55 with overweight or obesity, which found that staying on Zepbound for weight management lowered healthcare costs over time relative to similar untreated adults, driven in part by fewer hospital admissions and emergency department visits. For adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, these lower costs translate into meaningful savings as early as 12 months into treatment. This is the first study of its kind in this age group, and the results were published in Diabetes, Obesity and Metabolism. The study estimated cost differences over time, excluding Zepbound costs, using two established methods. Both approaches yielded, on average, lower monthly healthcare costs with sustained Zepbound use versus those who are untreated. At six months, costs were up to 15% lower. The difference widened by 12 months, with an estimated difference of up to $607 per patient, per month, reflecting on average up to 38% lower costs than those not treated. In the primary analysis, adults older than 55 treated with Zepbound had lower rates of hospital admissions and emergency department visits across every follow-up period, and numerically higher rates of routine outpatient and office visits, consistent with greater engagement in routine care. Beginning at six months, estimated healthcare cost savings nearly covered the Medicare GLP-1 Bridge program's monthly treatment cost of $195 per patient, per month. Starting at 12 months, estimated healthcare cost savings exceeded the cost of Zepbound treatment, suggesting that sustained treatment in an aging population may lead to meaningful cost savings.